Compare ARLO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | PCRX |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2010 |
| Metric | ARLO | PCRX |
|---|---|---|
| Price | $11.85 | $36.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $20.33 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.3M | 904.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 107.44 |
| EPS | 0.17 | ★ 0.89 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $11.76 | $2.00 |
| Revenue Next Year | $5.56 | $6.32 |
| P/E Ratio | $70.71 | ★ $40.99 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $11.05 | $18.80 |
| 52 Week High | $16.89 | $36.67 |
| Indicator | ARLO | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 82.36 |
| Support Level | N/A | $22.00 |
| Resistance Level | $13.95 | $36.67 |
| Average True Range (ATR) | 0.78 | 0.04 |
| MACD | -0.14 | -0.38 |
| Stochastic Oscillator | 5.67 | 86.67 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. Its cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter, from any location with a Wi-Fi or cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.